Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 28;13(5):736.
doi: 10.3390/brainsci13050736.

Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study

Odette Fründt  1 , Anne-Marie Hanff  2   3   4 , Annika Möhl  5 , Tobias Mai  6 , Christiane Kirchner  1 , Ali Amouzandeh  1 , Carsten Buhmann  7 , Rejko Krüger  2   8   9 , Martin Südmeyer  1   10
Affiliations

Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study

Odette Fründt et al. Brain Sci. .

Abstract

Data on the use of device-aided therapies (DATs) in people with Parkinson's disease (PwP) are scarce. Analyzing data from the Care4PD patient survey, we (1) evaluated application frequency and type of DAT in a larger, nationwide, cross-sectoral PwP sample in Germany; (2) analyzed the frequency of symptoms indicative for advanced PD (aPD) and need for DAT amongst the remaining patients and (3) compared the most bothersome symptoms and need for professional long-term care (LTC) of patients with and without suspected aPD. Data from 1269 PwP were analyzed. In total, 153 PwP (12%) received DAT, mainly deep brain stimulation (DBS). Of the remaining 1116 PwP without DAT, >50% fulfilled at least one aPD criterion. Akinesia/rigidity and autonomic problems were most bothersome for PwP with and without suspected aPD, with more tremor in the non-aPD and more motor fluctuations and falls in the aPD group. To recapitulate, the German DAT application rate is rather low, although a large proportion of PwP fulfills aPD criteria indicating a need for intensified treatment strategies. Many reported bothersome symptoms could be overcome with DAT with benefits even for LTC patients. Thus, precise and early identification of aPD symptoms (and therapy-resistant tremor) should be implemented in future DAT preselection tools and educational trainings.

Keywords: Parkinson’s disease; advanced; deep brain stimulation; device-aided therapies; disease progression; infusion therapies; medication pump.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report regarding this manuscript. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Parkinson’s symptoms rated as most bothersome (3 answers allowed, total n = 906) are depicted as percentage (%) of participants per group with (aPD, n = 492, blue) and without suspected advanced Parkinson’s disease (n-aPD, n = 414, orange). Right side: motor symptoms, left side: non-motor symptoms. Significant p-values of group comparisons are given. “Others” includes, e.g., fatigue, pain, mental/concentration problems, vision problems, inner restlessness, freezing or camptocormia (free text answers). This figure refers to question #8 (see Supplementary Materials). Data on dyskinesia (“involuntary movements”) are reported elsewhere in this manuscript.
See this image and copyright information in PMC

References

    1. Fasano A., Fung V.S.C., Lopiano L., Elibol B., Smolentseva I.G., Seppi K., Takats A., Onuk K., Parra J.C., Bergmann L., et al. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19:50. doi: 10.1186/s12883-019-1276-8. - DOI - PMC - PubMed
    1. Antonini A., Stoessl A.J., Kleinman L.S., Skalicky A.M., Marshall T.S., Sail K.R., Onuk K., Odin P.L.A. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: A multi-country Delphi-panel approach. Curr. Med. Res. Opin. 2018;34:2063–2073. doi: 10.1080/03007995.2018.1502165. - DOI - PubMed
    1. Santos-Garcia D., de Deus Fonticoba T., Suarez Castro E., Aneiros Diaz A., McAfee D. 5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson’s Treatment. Park. Dis. 2020;2020:7537924. doi: 10.1155/2020/7537924. - DOI - PMC - PubMed
    1. Antonini A., Odin P., Schmidt P., Cubillos F., Standaert D.G., Henriksen T., Jimenez-Shahed J., Alobaidi A., Jalundhwala Y.J., Bao Y., et al. Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson’s disease patients inadequately controlled on oral medications. Park. Relat. Disord. 2021;92:59–66. doi: 10.1016/j.parkreldis.2021.10.009. - DOI - PubMed
    1. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., Daniels C., Deutschlander A., Dillmann U., Eisner W., et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med. 2006;355:896–908. doi: 10.1056/NEJMoa060281. - DOI - PubMed

LinkOut - more resources